The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Promising Treatment for PNH Patients

• The United States Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to NM5072 for the treatment of anemia in PNH patients.

• The ODD provides NM5072 with a range of benefits, including financial incentives, regulatory support, extended market exclusivity, and extended patent life, ensuring that this groundbreaking treatment can reach those who need it.

• NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway (AP) while maintaining the integrity of the classical pathway required…